Furthermore, sorafenib did not inhibit tumor recruitment of macrophages (CD68 and F4/80 markers; Figure 5A), Fas, and lysozymes 1 and 2 (Figure 5B, 5C), which are important for macrophage anti-tumor activity [44,45]. Here, FAS is linked to neoplasm.